Clinical features and predictors of atrial fibrillation in patients with light-chain or transthyretin cardiac amyloidosis.
Amyloidosis
Atrial fibrillation
Cardiomyopathy
Light-chain
Transthyretin
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
30
01
2022
received:
16
09
2021
accepted:
07
02
2022
pubmed:
19
2
2022
medline:
6
5
2022
entrez:
18
2
2022
Statut:
ppublish
Résumé
The study aimed to investigate the prevalence, phenotypic characteristics, and predictors of atrial fibrillation (AF) in patients presenting with cardiac amyloidosis (CA) of light-chain (AL) or transthyretin (ATTR) type. Clinical, biochemical, and echocardiographic data of patients presenting with CA between 2005 and 2020 were retrospectively collected. CA staging was based on established biomarker systems. Binomial logistic regression was run to analyse the effects of clinical variables on the likelihood of AF. The study included 133 patients [53% AL, 41% wild-type (wt) ATTR-CA, & 6% hereditary ATTR-CA]. Mean age was 71 years, and 80% were male patients. AF was diagnosed in 64 (48%) patients (28% in AL-CA, 80% in wtATTR, 13% in hATTR, P < 0.001). Patients with AF were older (74 vs. 69 years, P < 0.001), more likely to have wtATTR-CA (67 vs. 16%, P < 0.001), exhibited more often New York Heart Association ≥ III symptoms (66 vs. 45%, P = 0.02) and carried a higher burden of comorbidities. AF patients had lower left ventricular ejection fraction (47 vs. 53%, P < 0.005), higher left atrial volume index (54 vs. 46 mL/m Atrial fibrillation affects nearly half of all patients with CA. Patients presenting with AF have more severe symptoms and higher burden of comorbidities. ATTR type of amyloidosis is the strongest predictor of AF. Prospective screening for occult AF may be considered in ATTR-CA.
Identifiants
pubmed: 35178887
doi: 10.1002/ehf2.13851
pmc: PMC9065861
doi:
Substances chimiques
Prealbumin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1740-1748Informations de copyright
© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
ESC Heart Fail. 2022 Jun;9(3):1740-1748
pubmed: 35178887
J Am Coll Cardiol. 2019 Jun 11;73(22):2910-2911
pubmed: 31171104
Amyloid. 2019 Sep;26(3):128-138
pubmed: 31172799
J Am Heart Assoc. 2013 Apr 22;2(2):e000098
pubmed: 23608605
Amyloid. 2018 Jun;25(2):136
pubmed: 29529882
Circ Res. 2017 Apr 28;120(9):1501-1517
pubmed: 28450367
ESC Heart Fail. 2018 Oct;5(5):772-779
pubmed: 29916559
J Am Coll Cardiol. 2018 Oct 23;72(17):2040-2050
pubmed: 30336828
Eur Heart J. 2004 Jul;25(14):1237-41
pubmed: 15246642
Blood. 2013 Apr 25;121(17):3420-7
pubmed: 23479568
Eur Heart J. 2018 Aug 7;39(30):2799-2806
pubmed: 29048471
Amyloid. 2021 Mar;28(1):12-18
pubmed: 32981389
J Am Coll Cardiol. 2019 Jun 11;73(22):2911-2913
pubmed: 31171105
Eur Heart J. 2015 Oct 7;36(38):2585-94
pubmed: 26224076
Circ Cardiovasc Imaging. 2016 Aug;9(8):
pubmed: 27511979
Circulation. 2009 May 12;119(18):2490-7
pubmed: 19414641
JACC Clin Electrophysiol. 2020 Apr;6(4):351-361
pubmed: 32327068
Europace. 2020 Feb 1;22(2):259-264
pubmed: 32031230
J Am Coll Cardiol. 2018 Jan 30;71(4):463-464
pubmed: 29389364
Circulation. 2007 Nov 20;116(21):2420-6
pubmed: 17984380
Eur Heart J. 2017 Oct 07;38(38):2879-2887
pubmed: 29019612
Eur Heart J. 2021 Feb 1;42(5):373-498
pubmed: 32860505
Amyloid. 2015;22(3):147-55
pubmed: 25997105
JACC Heart Fail. 2014 Apr;2(2):113-22
pubmed: 24720917
Circulation. 2021 Mar 30;143(13):1335-1337
pubmed: 33779268
Circulation. 2002 Oct 15;106(16):2091-7
pubmed: 12379579
Eur Heart J. 2021 Apr 21;42(16):1554-1568
pubmed: 33825853
JACC Heart Fail. 2020 Sep;8(9):712-724
pubmed: 32653448
ESC Heart Fail. 2020 Apr;7(2):705-707
pubmed: 31965737